Insite Vision Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Insite Vision Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Awashonks who wrote (937)	5/29/1999 12:08:00 PM
From: David Bogdanoff	Read Replies (2) of 1060

A; Thanks for info. You wrote: <<2. There will be an additional Phase II trial of 205 to a generic glaucoma patient group that will be bigger than the existing phase II trial was. Should go about 6 months. Instead of only testing steroid induced glaucoma, it tests patients with all types of glaucoma. Tests an "expanded indication". A big deal. So I don't know when Phase III trials will begin, but things are looking good. If they can treat all glaucoma patients with 205 we're in heaven. >> A phase II trial is for determining optimum dose and it is difficult to see why more heterogenous group which includes the patients of the first phase II study would be done since dosage is already being determined on them. A phase II study of entirely different patients who may need a different dosage would make sense. Comments anyone? David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next